Tazverik treats epithelioid sarcoma, a rare form of soft tissue cancer, by stopping cancer cells from spreading.
The FDA said that half of patients who have the rare cancer have a metastatic form by the time they are diagnosed, meaning it has spread to other parts of their body, which can be life-threatening.
Epizyme, a Massachusetts-based drugmaker, priced Tazverik at $15,500 per month, or $186,000 for a year’s supply, according to Endpoints News.
The FDA is requiring Tazverik to be dispensed with a medication guide that details the risks associated with the treatment, and it is only approved for patients over 16 years.
Read the full news release here.
More articles on pharmacy:
BCBS, Civica Rx create subsidiary to cut generic drug costs
PhRMA spent a record $29M on lobbying in 2019
Former Insys CEO gets 30 months in prison
